RNAi therapeutics: an antiviral strategy for human infections.
Journal
Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
07
05
2020
revised:
20
09
2020
accepted:
24
09
2020
pubmed:
11
11
2020
medline:
12
10
2021
entrez:
10
11
2020
Statut:
ppublish
Résumé
Gene silencing induced by RNAi represents a promising antiviral development strategy. This review will summarise the current state of RNAi therapeutics for treating acute and chronic human virus infections. The gene silencing pathways exploited by RNAi therapeutics will be described and include both classic RNAi, inducing cytoplasmic mRNA degradation post-transcription and novel RNAi, mediating epigenetic modifications at the transcription level in the nucleus. Finally, the challenge of delivering gene modifications via RNAi will be discussed, along with the unique characteristics of respiratory versus systemic administration routes to highlight recent advances and future potential of RNAi antiviral treatment strategies.
Identifiants
pubmed: 33171339
pii: S1471-4892(20)30092-8
doi: 10.1016/j.coph.2020.09.011
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
121-129Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.